Freedom251 › AI Drug Discovery Software
Chemistry42
Facts from Insilico Medicine's own pages
- ADMET and selectivity
- Predictive models profile and optimize ADMET and selectivity, including as standalone tools or within generative experiments. · pharma.ai, 14 Nov 2026
- Audience and access
- The page has a dedicated offering for academia and startups, and links to sign up and log in through Chemistry42 Cloud. · pharma.ai, 14 Nov 2026
- Binding free energy
- Alchemistry computes relative protein-ligand binding free energy to help prioritize lead compounds. · pharma.ai, 14 Nov 2026
- Building blocks
- The retrosynthesis tool includes a collection of 300,000 commercially available building blocks. · pharma.ai, 14 Nov 2026
- Concurrency limit
- Tokens govern how many experiments users in an organization can run simultaneously; token requirements vary by experiment settings. · pharma.ai, 14 Nov 2026
- Data hosting
- The privacy policy states SaaS data is processed in Seoul for cloud.chemistry42.com subscriptions and in Ireland for lab.chemistry42.com subscriptions. · pharma.ai, 14 Nov 2026
- External tools
- The platform can be customized with external QSAR models, MD simulators, and in-house databases. · pharma.ai, 14 Nov 2026
- Generative chemistry
- The platform supports de novo design, hit optimization, scaffold hopping, and R-group search. · pharma.ai, 14 Nov 2026
- Model training
- Users can train predictive models on their own data, including in vitro activity or simulation data. · pharma.ai, 14 Nov 2026
- Molecular dynamics
- MDFlow provides simulation workflows for biomolecules and complexes, from system building and sampling through reporting. · pharma.ai, 14 Nov 2026
- Purpose
- Chemistry42 is a small-molecule drug discovery platform for hit identification, hit-to-lead, and lead optimization. · pharma.ai, 14 Nov 2026
- Retrosynthesis
- It predicts synthetic routes for uploaded or generated molecular structures using expert-annotated reaction templates. · pharma.ai, 14 Nov 2026
- Security caveat
- The privacy policy says the company uses commercially acceptable protective measures but cannot guarantee absolute security. · pharma.ai, 14 Nov 2026
- Subscription use
- The terms limit subscription use to internal drug discovery by the customer organization and its affiliates. · pharma.ai, 14 Nov 2026
- Support
- The terms say Insilico will use reasonable commercial efforts to host, support, and maintain the subscription. · pharma.ai, 14 Nov 2026
Where Chemistry42 stands on Freedom251
- AI Drug Discovery Software#9 of 33